 Your new post is loading...
Your new post is loading...
|
Scooped by
Ed Rybicki
May 1, 2020 7:08 AM
|
How can enough Covid-19 vaccine be made quickly for 7.8 billion people and should New Zealand produce its own vaccine?
|
|
Scooped by
Ed Rybicki
May 1, 2020 7:05 AM
|
A group of pandemic modeling experts from the University of Sydney's Faculty of Engineering have published new research that simulated viral influenza outbreaks to examine the efficacy of pandemic interventions in the absence of a tailored vaccine.
|
|
Scooped by
Ed Rybicki
May 1, 2020 7:04 AM
|
A ventilator prototype that uses low-cost off the shelf parts could help alleviate concerns about shortages of medical equipment.
|
|
Scooped by
Ed Rybicki
May 1, 2020 7:03 AM
|
Reserchers have put together a plan to address the spread of fake news, racism, and stress for life in the COVID-19 pandemic.
|
|
Scooped by
Ed Rybicki
May 1, 2020 7:03 AM
|
Serum envisages a price of Rs 1,000 per vaccine but governments would give it to people without charge...
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:18 AM
|
Drugmaker Eli Lilly said it expects to begin human testing as soon as next month for an experimental Covid-19 treatment that uses antibodies derived from the blood of people who have recovered from the new coronavirus.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:14 AM
|
As one of the world's biggest vaccine makers, India could play a big role in stopping the virus.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:13 AM
|
Recent viral outbreaks with significant mortality such as Ebola virus (EBOV), SARS-coronavirus (CoV), and MERS-CoV reinforced the need for effective antiviral therapeutics to control future epidemics.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:12 AM
|
Flipping over could make it easier for COVID-19 patients to breathe. A new trial will try to bring some hard data to back up the potential treatment.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:11 AM
|
This article appeared in the New York Times. Read the full story here. As parents around the country cancel well-child checkups to avoid coronavirus exposure, public health experts fear they are inadvertently sowing the seeds of another health crisis.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:10 AM
|
The Serum Institute of India said on Tuesday it plans this year to produce up to 60 million doses of a potential vaccine against the new coronavirus that is under clinical trial in Britain.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:10 AM
|
There are around 80 vaccines currently in development.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:09 AM
|
When a type of bacteria has resistance to one antibiotic, that can set it up to become a multidrug-resistant strain, researchers say.
|
|
|
Scooped by
Ed Rybicki
May 1, 2020 7:07 AM
|
AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. The collaboration aims to bring to patients the potential vaccine, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford. Under the agreement, AstraZeneca would be responsible for development and worldwide manufacturing and distribution of the vaccine if the clinical trials prove successful in showing the vaccine is effective. Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “As COVID-19 continues its grip on the world, the need for a vaccine to defeat the virus is urgent. This collaboration brings together the University of Oxford’s world-class expertise in vaccinology and AstraZeneca’s global development, manufacturing and distribution capabilities. Our hope is that, by joining forces, we can accelerate the globalisation of a vaccine to combat the virus and protect people from the deadliest pandemic in a generation.” Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “The University of Oxford and AstraZeneca have a longstanding relationship to advance basic research and we are hugely excited to be working with them on advancing a vaccine to prevent COVID-19 around the world. We are looking forward to working with the University of Oxford and innovative companies such as Vaccitech, as part of our new partnership.” Alok Sharma, UK Business Secretary, said: “This collaboration between Oxford University and AstraZeneca is a vital step that could help rapidly advance the manufacture of a coronavirus vaccine. It will also ensure that, should the vaccine being developed by Oxford University’s Jenner Institute work, it will be available as early as possible, helping to protect thousands of lives from this disease.” Professor Sir John Bell, Regius Professor of Medicine at Oxford University, said: “Our partnership with AstraZeneca will be a major force in the struggle against pandemics for many years to come. We believe that together we will be in a strong position to start immunising against coronavirus once we have an effective approved vaccine. Sadly, the risk of new pandemics will always be with us and the new research centre will enhance the world’s preparedness and our speed of reaction the next time we face such a challenge.” Professor Louise Richardson, Vice-Chancellor of Oxford University, said: “Like my colleagues all across Oxford, I am deeply proud of the work of our extraordinarily talented team of academics in the Jenner Institute and the Oxford Vaccine Group. They represent the best tradition of research, teaching and contributing to the world around us, that has been the driving mission of the University of Oxford for centuries. Like people all across the country, we are wishing them success in developing an effective vaccine. If they are successful, our partnership with AstraZeneca will ensure that the British people and people across the world, especially in low and middle income countries, will be protected from this terrible virus as quickly as possible.” The potential vaccine entered Phase I clinical trials last week to study safety and efficacy in healthy volunteers aged 18 to 55 years, across five trial centres in Southern England. Data from the Phase I trial could be available next month. Advancement to late-stage trials should take place by the middle of this year.
|
|
Scooped by
Ed Rybicki
May 1, 2020 7:05 AM
|
Winter the llama is an unlikely ally in the search for an effective COVID-19 treatment. The latest advance is a synthetic antibody.
|
|
Scooped by
Ed Rybicki
May 1, 2020 7:04 AM
|
This isn’t just about saving lives. It’s also about power, profit and national prestige.
|
|
Scooped by
Ed Rybicki
May 1, 2020 7:03 AM
|
An expert warns there is "nothing more valuable" in the world today than a way to prevent the disease.
|
|
Scooped by
Ed Rybicki
May 1, 2020 7:02 AM
|
BEGIN ARTICLE PREVIEW: Logo of Swiss pharmaceutical group Lonza is seen in BaselMore(Reuters) – Moderna Inc and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:17 AM
|
A public health catch-22 In 2016, the serotype 2 component of the oral poliovirus vaccine given to children was withdrawn. This measure was taken to prevent vaccine-associated disease outbreaks caused by mutation in the live attenuated vaccine. Children around the world now have poor immunity to serotype 2 poliovirus because the inactivated vaccine is far less effective and a new oral vaccine is not yet ready. Using a statistical model, Macklin et al. discovered that most current outbreaks of polio in several countries across Asia and sub-Saharan Africa are likely associated with the serotype 2 vaccine strain (see the Perspective by Donlan and Petri).
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:14 AM
|
Researchers make the case for a saliva test for COVID-19, rather than the nasal swabs currently in use.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:13 AM
|
Regulatory approval of challenge tests and money for redundant manufacturing would help.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:12 AM
|
More than 100 years ago, a school teacher in a small north island town wrote to the government to tell them how fast influenza had hit.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:11 AM
|
Using microchip technology boosts the accuracy of antibody testing of patients recovered from COVID-19. That would help find convalescent plasma donors.
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:10 AM
|
‘We will have coronavirus in the fall. I am convinced of that,’ Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said...
|
|
Scooped by
Ed Rybicki
April 29, 2020 5:10 AM
|
So many candidates, so little time...Can the world find a good covid-19 vaccine quickly enough?
And can it mass-produce it fairly if it does?
|
Scoop.it!
